- Home
- KPRX vs NUAI Comparison
KPRX vs NUAI Comparison
Compare KPRX & NUAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KPRX | NUAI |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 233.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KPRX | NUAI |
|---|---|---|
| Price | $2.05 | $4.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 51.8K | ★ 7.0M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $843,029.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.89 |
| 52 Week Low | $1.77 | $0.32 |
| 52 Week High | $4.18 | $12.29 |
Technical Indicators
Market Signals| Indicator | KPRX | NUAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 48.74 |
| Support Level | $1.80 | $3.87 |
| Resistance Level | $2.17 | $4.53 |
| Average True Range (ATR) | 0.14 | 0.61 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 59.60 | 49.52 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About NUAI New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.